In vivo distribution of integrins in renal cell carcinoma: integrin-phenotype alteration in different degrees of tumor differentiation and VLA-2 involvement in tumor metastasis.
We studied 23 renal cell carcinomas and two normal kidney tissues by immunohistochemistry using monoclonal antibodies against subunits of the VLA integrins (VLA-1 to VLA-6) and CD51. All integrins investigated in our study, except VLA-4 (ubiquitous negative), were distributed in different patterns in tumors assayed. We found a correlation between VLA-2 expression and site of tissue; primary tumor cells expressed no VLA-2 integrin, whereas tumor cells from metastatic tissues exhibited VLA-2 positivity (P < .009). Additionally, the expression of VLA-3 and VLA-5 correlated with tumor grading; both integrins were undetectable in G1 tumors but widely expressed in G2 and G3 tumors (VLA-3, p < .000; VLA-5, p < .005). Our results suggest that VLA-2 integrin is involved in metastasis of RCC and that poorly differentiated tumor cells have a different integrin phenotype when compared to normal or highly differentiated tumor cells.
Anastassiou
G
G
Department of Hematology-Oncology, Medizinische Hochschule Hannover, Germany.
Duensing
S
S
Steinhoff
G
G
Kirchner
H
H
Ganser
A
A
Atzpodien
J
J
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal; D002292:Carcinoma, Renal Cell / Q000378:metabolism* / Q000473:pathology / Q000556:secondary / Q000628:therapy; D002454:Cell Differentiation; D002467:Cell Nucleus / Q000378:metabolism; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007668:Kidney / Q000378:metabolism; D007680:Kidney Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011379:Prognosis; D016029:Receptors, Very Late Antigen / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D016029:Receptors, Very Late Antigen